达仁堂: 达仁堂2025年第四次董事会决议公告
Core Points - The company held its fourth board meeting of 2025 on June 20, with all 9 directors present, complying with legal requirements [1] - The board approved related party transactions, including a share custody agreement with Tianjin Pharmaceutical Asset Management Co., Ltd. and a lease agreement with Tianjin Pharmaceutical Taiping Co., Ltd. [1][2] - The board appointed Zhao Liyang as the company's securities affairs representative, with a background in management and experience in various pharmaceutical companies [2]